Search research articles
Contact Us
Filters
Showing results (11-20 of 101) with videos related to
Page
of 11
Sort By:
Cancer Treatment Reviews
|
April 10, 2020
Thymic epithelial tumors: From biology to treatment
Fabio Conforti, Laura Pala, Giuseppe Giaccone, et al.
Journal of the National Cancer Institute
|
September 3, 2025
Response to Sahin, Guven and Aksoy
Edoardo Botteri, Fabio Conforti, Erica K Sloan, et al.
Anti-Cancer Drugs
|
February 4, 2020
Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma
Laura Pala, Fabio Conforti, Emilia Cocorocchio, et al.
Future Oncology (London, England)
|
September 12, 2017
Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib
Tommaso De Pas, Laura Pala, Chiara Catania, et al.
Cancers
|
April 3, 2021
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Pier Francesco Ferrucci, Laura Pala, Fabio Conforti, et al.
Immunopharmacology and Immunotoxicology
|
March 10, 2012
Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice
Roberto Castelli, Antonino Cannavò, Fabio Conforti, et al.
Expert Opinion on Investigational Drugs
|
August 12, 2022
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials
Fabio Conforti, Laura Pala, Tommaso De Pas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2018
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity
Guanhua Rao, In-Kyu Kim, Fabio Conforti, et al.
Cancers
|
July 14, 2023
Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline <i>BRCA1/2</i> Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies
Marta Nerone, Lorenzo Rossi, Rosaria Condorelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 2, 2015
Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling
Fabio Conforti, Yisong Wang, Jose A Rodriguez, et al.
Page
of 11
Search research articles
Search
Showing results (11-20 of 101) with videos related to
Sort By:
Page
of 11
Cancer Treatment Reviews
|
April 10, 2020
Thymic epithelial tumors: From biology to treatment
Fabio Conforti, Laura Pala, Giuseppe Giaccone, et al.
Journal of the National Cancer Institute
|
September 3, 2025
Response to Sahin, Guven and Aksoy
Edoardo Botteri, Fabio Conforti, Erica K Sloan, et al.
Anti-Cancer Drugs
|
February 4, 2020
Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma
Laura Pala, Fabio Conforti, Emilia Cocorocchio, et al.
Future Oncology (London, England)
|
September 12, 2017
Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib
Tommaso De Pas, Laura Pala, Chiara Catania, et al.
Cancers
|
April 3, 2021
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Pier Francesco Ferrucci, Laura Pala, Fabio Conforti, et al.
Immunopharmacology and Immunotoxicology
|
March 10, 2012
Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice
Roberto Castelli, Antonino Cannavò, Fabio Conforti, et al.
Expert Opinion on Investigational Drugs
|
August 12, 2022
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials
Fabio Conforti, Laura Pala, Tommaso De Pas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2018
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity
Guanhua Rao, In-Kyu Kim, Fabio Conforti, et al.
Cancers
|
July 14, 2023
Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline <i>BRCA1/2</i> Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies
Marta Nerone, Lorenzo Rossi, Rosaria Condorelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 2, 2015
Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling
Fabio Conforti, Yisong Wang, Jose A Rodriguez, et al.
Page
of 11